Sleep

Age, frequent snoring, hypertension, and poor glycemic control are associated with excessive daytime sleepiness.

The new approval continues to expand the therapeutic potential of GLP-1 medications such as tirzepatide, now being deemed effective in patients with obstructive sleep apnea.

Treatment for RLS includes lifestyle modifications, medication, and in some cases, non-drug therapies, aiming to reduce symptoms and improve sleep and daytime functioning.

Tryptophan, found in turkey and other foods, affects serotonin and melatonin production.

Insomnia exhibits a dose-response relationship with AF recurrence, indicating that an increased number of insomnia symptoms is associated with heightened probability of AF recurrence.

Low levels of vitamin D was linked with increased obstructive Apnea-Hypopnea Index scores.

Patients aged 7 years and older can now be treated for their cataplexy or excessive daytime sleepiness with the extended-release oral formulation.

Treatment with tirzepatide has led not only to significant reductions in excess body weight, but also improvements in blood pressure and reduction of inflammatory markers.

AI-enabled remote cardiac monitoring offers continuous data on heart activity, allowing for the early detection of arrhythmias, optimized treatment timing, and improved sleep-related heart health management.

Poor sleep quality is directly related to mortality risk before adjusting for lifestyle or health-related factors, and dementia was noticeably linked to mortality risk in older White males.

Pharmacists can help identify potential drug-drug interactions and adverse reactions, and advise patients when to seek further treatment

The ADA Clinical Practice Recommendations added sleep assessment for precision medicine in type 2 diabetes, supporting the wealth of information surrounding the association.

The findings show that those with higher plasma homocysteine concentrations experienced more sleep apnea events per hour compared with those with lower concentrations.

Based on these results, tirzepatide could be first medication approved for treatment of obstructive sleep apnea in patients with obesity.

Despite the finding, the authors suggest further research is done to better understand the mechanisms behind the interactions between asthma, sleep, and depression.

With the current social media trend of the “Sleepy-Girl Mocktail” claiming to provide quality sleep, is this trend fact or faux as a quality sleep aid?

Eli Lilly and Company will submit results of the study to support tirzepatide (Zepbound) for treatment of obstructive sleep apnea later this year.

Several studies on valerian have been conducted in the past 50 years for indications varying from insomnia, anxiety, restless leg syndrome, headaches, and more.

Stephanie Ashraf, MD, offered clinical experience in managing insomnia at the American Medical Women’s Association (AMWA) 2024 Annual Meeting.

In some instances, metabolites can predict risk in patients who still have normal glucose biomarkers.

Investigators found genetic evidence that certain sleep behaviors can be risk factors for lifespan.

Increased waist circumference and high blood pressure can disrupt circadian rhythm, which can increase risk of progression to poor renal outcomes.

Benzodiazepines have proven effective in managing anxiety and insomnia, but they heighten risk of falls, cognitive impairment, functional decline, and mortality among older adults.

Because medications to treat these conditions are often controlled substances, including pharmacists on the multidisciplinary team (MDT) is invaluable.